Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Taxes (2016 - 2025)

Amphastar Pharmaceuticals has reported Current Taxes over the past 13 years, most recently at $239000.0 for Q4 2025.

  • Quarterly results put Current Taxes at $239000.0 for Q4 2025, down 97.53% from a year ago — trailing twelve months through Dec 2025 was $239000.0 (down 97.53% YoY), and the annual figure for FY2025 was $239000.0, down 97.53%.
  • Current Taxes for Q4 2025 was $239000.0 at Amphastar Pharmaceuticals, down from $5.6 million in the prior quarter.
  • Over the last five years, Current Taxes for AMPH hit a ceiling of $31.1 million in Q3 2023 and a floor of $239000.0 in Q4 2025.
  • Median Current Taxes over the past 5 years was $4.3 million (2021), compared with a mean of $7.1 million.
  • Biggest five-year swings in Current Taxes: surged 2864.15% in 2023 and later tumbled 97.53% in 2025.
  • Amphastar Pharmaceuticals' Current Taxes stood at $9.1 million in 2021, then crashed by 49.66% to $4.6 million in 2022, then plummeted by 64.8% to $1.6 million in 2023, then skyrocketed by 500.62% to $9.7 million in 2024, then tumbled by 97.53% to $239000.0 in 2025.
  • The last three reported values for Current Taxes were $239000.0 (Q4 2025), $5.6 million (Q3 2025), and $1.0 million (Q2 2025) per Business Quant data.